Literature DB >> 30713792

Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth.

Apostolos G Pappas1, Sophia Magkouta1, Ioannis S Pateras2, Ioannis Skianis3, Charalampos Moschos1, Maria Eleni Vazakidou1, Katherina Psarra4, Vassilis G Gorgoulis2,5,6, Ioannis Kalomenidis1.   

Abstract

Versican promotes experimental tumor growth through cell- and non cell-autonomous mechanisms. Its role in mesothelioma progression has not been investigated so far. In this study we investigated the impact of tumor-derived versican in mesothelioma progression and the underlying mechanism of its action. For this purpose, versican-silenced or control ΑΕ17 and ΑΒ1 murine mesothelioma cells were intrapleuraly injected into syngeneic mice, in order to create pleural mesotheliomas and pleural effusions. Intratumoral and pleural immune subsets were assessed using flow cytometry. Mesothelioma cells were co-cultured with syngeneic macrophages to examine versican's impact on their interaction and endothelial cells to assess the effect of versican in endothelial permeability. Versican expression was assessed in human mesotheliomas and mesothelioma-related pleural effusions and benign pleural tissue and effusions. We observed that, versican silencing reduced mesothelioma mass and pleural fluid volume by affecting tumor cell proliferation and apoptosis in vivo, while tumor cell growth remained intact in vitro, and limited pleural vascular permeability. Mice harboring versican-deficient tumors presented fewer tumor/pleural macrophages and neutrophils, and fewer pleural T-regulatory cells, compared to the control animals. Macrophages co-cultured with versican-deficient mesothelioma cells were polarized towards M1 anti-tumor phenotype and demonstrated increased tumor cell phagocytic capacity, compared to macrophages co-cultured with control tumor cells. In co-culture, endothelial monolayer permeability was less effectively stimulated by versican-deficient cells than control cells. Versican was over-expressed in human mesothelioma tissue and mesothelioma-associated effusion. In conclusion, tumor cell-derived versican stimulates mesothelioma progression by shaping a tumor friendly inflammatory milieu, mainly by blunting macrophage anti-tumor activities.

Entities:  

Keywords:  Chondroitin sulfate proteoglycan core protein 2; extra-cellular matrix; monocytes/macrophages; pleural neoplasms; tumor-immunology

Year:  2018        PMID: 30713792      PMCID: PMC6343798          DOI: 10.1080/2162402X.2018.1537427

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  35 in total

1.  Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4.

Authors:  J D Sandy; J Westling; R D Kenagy; M L Iruela-Arispe; C Verscharen; J C Rodriguez-Mazaneque; D R Zimmermann; J M Lemire; J W Fischer; T N Wight; A W Clowes
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

Review 2.  Pathogen recognition and innate immunity.

Authors:  Shizuo Akira; Satoshi Uematsu; Osamu Takeuchi
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

3.  Isolation of endothelial cells from fresh tissues.

Authors:  Judy R van Beijnum; Mat Rousch; Karolien Castermans; Edith van der Linden; Arjan W Griffioen
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

Review 4.  Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.

Authors:  Daniel H Sterman; Steven M Albelda
Journal:  Respirology       Date:  2005-06       Impact factor: 6.424

Review 5.  Malignant mesothelioma.

Authors:  Bruce W S Robinson; Arthur W Musk; Richard A Lake
Journal:  Lancet       Date:  2005 Jul 30-Aug 5       Impact factor: 79.321

6.  Versican/PG-M G3 domain promotes tumor growth and angiogenesis.

Authors:  Peng-Sheng Zheng; Jianping Wen; Lee Cyn Ang; Wang Sheng; Alicia Viloria-Petit; Yelina Wang; Yaojiong Wu; Robert S Kerbel; Burton B Yang
Journal:  FASEB J       Date:  2004-02-06       Impact factor: 5.191

7.  A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.

Authors:  Georgios T Stathopoulos; Ioannis Psallidas; Ardiana Moustaki; Charalampos Moschos; Androniki Kollintza; Sophia Karabela; Ilias Porfyridis; Spyridoula Vassiliou; Marilena Karatza; Zongmin Zhou; Myungsoo Joo; Timothy S Blackwell; Charis Roussos; Daniel Graf; Ioannis Kalomenidis
Journal:  J Natl Cancer Inst       Date:  2008-10-07       Impact factor: 13.506

8.  IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.

Authors:  Connie Jackaman; Christine S Bundell; Beverley F Kinnear; Alison M Smith; Pierre Filion; Deborah van Hagen; Bruce W S Robinson; Delia J Nelson
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

9.  The isolation and characterization of murine macrophages.

Authors:  Xia Zhang; Ricardo Goncalves; David M Mosser
Journal:  Curr Protoc Immunol       Date:  2008-11

10.  The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050.

Authors:  J T Hodgson; D M McElvenny; A J Darnton; M J Price; J Peto
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

View more
  13 in total

1.  MTH1 favors mesothelioma progression and mediates paracrine rescue of bystander endothelium from oxidative damage.

Authors:  Sophia F Magkouta; Apostolos G Pappas; Photene C Vaitsi; Panagiotis C Agioutantis; Ioannis S Pateras; Charalampos A Moschos; Marianthi P Iliopoulou; Chrysavgi N Kosti; Heleni V Loutrari; Vassilis G Gorgoulis; Ioannis T Kalomenidis
Journal:  JCI Insight       Date:  2020-06-18

Review 2.  Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity.

Authors:  Athanasios Papadas; Garrett Arauz; Alexander Cicala; Joshua Wiesner; Fotis Asimakopoulos
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 3.  Matrix proteoglycans in tumor inflammation and immunity.

Authors:  Gauri Deb; Alexander Cicala; Athanasios Papadas; Fotis Asimakopoulos
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-25       Impact factor: 5.282

4.  VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.

Authors:  Guangyan Zhangyuan; Fei Wang; Haitian Zhang; Runqiu Jiang; Xuewen Tao; Decai Yu; Kangpeng Jin; WeiWei Yu; Yang Liu; Yin Yin; Jintao Shen; Qinfeng Xu; Wenjie Zhang; Beicheng Sun
Journal:  Oncogene       Date:  2019-10-11       Impact factor: 9.867

Review 5.  Proteoglycans and Immunobiology of Cancer-Therapeutic Implications.

Authors:  George Tzanakakis; Monica Neagu; Aristidis Tsatsakis; Dragana Nikitovic
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

Review 6.  ADAMTS proteases and the tumor immune microenvironment: Lessons from substrates and pathologies.

Authors:  Silvia Redondo-García; Carlos Peris-Torres; Rita Caracuel-Peramos; Juan Carlos Rodríguez-Manzaneque
Journal:  Matrix Biol Plus       Date:  2020-12-30

Review 7.  Stromal Protein-Mediated Immune Regulation in Digestive Cancers.

Authors:  Pia Gamradt; Christelle De La Fouchardière; Ana Hennino
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639

8.  COL1A1 Is a Potential Prognostic Biomarker and Correlated with Immune Infiltration in Mesothelioma.

Authors:  Cangang Zhang; Shanshan Liu; Xin Wang; Haiyan Liu; Xiaobo Zhou; Haibo Liu
Journal:  Biomed Res Int       Date:  2021-01-04       Impact factor: 3.411

Review 9.  Versican-A Critical Extracellular Matrix Regulator of Immunity and Inflammation.

Authors:  Thomas N Wight; Inkyung Kang; Stephen P Evanko; Ingrid A Harten; Mary Y Chang; Oliver M T Pearce; Carys E Allen; Charles W Frevert
Journal:  Front Immunol       Date:  2020-03-24       Impact factor: 7.561

10.  Identification of Key Genes in Gastric Cancer by Bioinformatics Analysis.

Authors:  Xinyu Chong; Rui Peng; Yan Sun; Luyu Zhang; Zheng Zhang
Journal:  Biomed Res Int       Date:  2020-09-21       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.